The price of BIO is predicted to go up -9.91%, based on the high correlation periods with BR. The similarity of these two price pattern on the periods is 95.43%.
BIO
BR
Bio-Rad is a leader in niche areas including quality controls, antigens, and digital PCR, and it has a strong razor-and-blade model in clinical diagnostics.
The noncontrolling stake in Sartorius gives Bio-Rad material economic exposure to the bioprocessing market, a highly regulated industry with attractive long-term secular growth trends.
Although one-off items have affected results in the recent past, such as a restructuring that began in 2017 and a cyberattack in 2019, the firm has since then made progress on improving its operating profitability.
Citigroup
2024-10-01
Price Target
$350 → $400
Upside
+18.45%